Drug Interactions in Transgendered Women

Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women

Transgender women living with Human Immunodeficiency Virus (HIV) may prioritize gender-affirming hormonal therapy over antiretroviral drug therapy. Hormonal therapy typically consists of oral estradiol and spironolactone, which induce drug-metabolizing enzymes after prolonged administration. This study evaluates the bi-directional potential drug interaction between the antiretroviral drug, doravirine, when co-administered with estradiol and spironolactone.

Pharmaceutical medication involved
Patients and healthy individuals accepted

Drug - Doravirine/Lamivudine/Tenofovir

100mg/300mg/300mg orally for one dose, daily

Drug - Spironolactone 100mg

200mg orally for two doses, twice-daily

Drug - Estradiol 2mg

4mg orally for two doses, twice-daily


Placebo for one dose, daily

A Prospective, Randomized, Three-period Crossover, Interaction Study to Evaluate the Pharmacokinetics of Doravirine and Tenofovir Disoproxil Fumarate Co-administered With Cross-sex Hormonal Therapy in Adult HIV-negative Transgender Women